Sotera Health Company announced its financial results for the fourth quarter and full year ended December 31, 2024. For Q4 2024, net revenues decreased 6.5% to $290 million, compared to $310 million in the prior-year quarter, as expected. Net income was $12 million, or $0.04 per diluted share, down from $39 million, or $0.14 per diluted share, in Q4 2023.
Full-year 2024 net revenues increased 4.9% to $1.10 billion, marking the 19th consecutive year of annual revenue growth for the company. Adjusted EBITDA for full-year 2024 increased 3.9% to $549 million, while Adjusted EPS was $0.70, a decrease of $0.02 from 2023. The company's net leverage ratio improved to 3.7x as of December 31, 2024, from 3.8x a year prior.
For 2025, Sotera Health provided an initial outlook, projecting constant currency revenue growth of 4.0% to 6.0% and Adjusted EBITDA growth of 4.5% to 6.5%. Adjusted EPS is expected to be in the range of $0.70 to $0.76. Capital expenditures are projected between $190 million and $210 million, with a focus on capacity expansion and NESHAP compliance.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.